Brought to you by 
Amarantus, Todos form Breakthrough Diagnostics to develop LymPro AD diagnostics
06 Dec 2018
Executive Summary
Amarantus BioScience Holdings Inc. and Todos Medical Ltd. agreed to form a new joint venture company called Breakthrough Diagnostics Inc., which will develop LymPro Test 2.0, a blood diagnostic that compares results of Amarantus' traditional LymPro test with those of amyloid PET imaging to diagnose Alzheimer’s disease (AD).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amarantus, Todos form Breakthrough Diagnostics to develop LymPro AD diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice